ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics platform tailored for the Indian market.

ChrysCapital acquires a 70.68% stake in Novartis India in a ₹1,446 crore deal, appoints new leadership and targets growth in branded generics.

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition,…